<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR1800016741</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2018-06-21</date_registration>
      <primary_sponsor> Peking University People's Hospital</primary_sponsor>
      <public_title>MLL–rearranged directed interferon-α intervention for relapse prophylaxis in acute leukemia after allogeneic stem cell transplantation</public_title>
      <acronym />
      <scientific_title>MLL–rearranged directed interferon-α intervention for relapse prophylaxis in acute leukemia after allogeneic stem cell transplantation</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2018-07-01</date_enrolment>
      <type_enrolment />
      <target_size>Intervention group:15;Observation group:15;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=28523</url>
      <study_type>Treatment study</study_type>
      <study_design>Non randomized control</study_design>
      <phase>II (Phase II study)</phase>
      <hc_freetext>Acute leukemia</hc_freetext>
      <i_freetext>Intervention group:IFN-α;Observation group:None;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Mo Xiaodong</firstname>
        <middlename />
        <lastname />
        <address>11 Xizhimen Street South, Xicheng District, Beijing, China</address>
        <city />
        <country1 />
        <zip>100044</zip>
        <telephone>+86 13810096698</telephone>
        <email>mxd453@163.com</email>
        <affiliation>Peking University People's Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Mo Xiaodong</firstname>
        <middlename />
        <lastname />
        <address>11 Xizhimen Street South, Xicheng District, Beijing, China</address>
        <city />
        <country1 />
        <zip>100044</zip>
        <telephone>+86 13810096698</telephone>
        <email>mxd453@163.com</email>
        <affiliation>Peking University People's Hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. MLL-positive acute leukemia,receiving allo-HSCT in CR1 or CR2;
2. MLL turned positive after allo-HSCT;
3. Without active GVHD, active infection,organ failure,and severe bone marrow suppression.</inclusion_criteria>
      <agemin>2</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. active GVHD;
2. severe infection;
3. organ failure;
4. severe bone marrow suppression;
5. died within 30 days after allo-HSCT;
6. enrolled in other trial within 1 month.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Relapse;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Leukemia-free survival;non-relapse mortality;Molecules response;Overall survival;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Capital’s Funds for Health Improvement and Research </source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>1990-01-01</approval_date>
        <contact_name>Wang Fang</contact_name>
        <contact_address>11 Xizhimen Street South, Xicheng District, Beijing, China</contact_address>
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>